Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

Video

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed the significance of the phase 3 CheckMate 9ER study results.

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium, combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival when compared with sunitinib (Sutent) among patients with previously treated advanced renal cell carcinoma (aRCC), regardless of sarcomatoid status.

In this open-label trial, adults with confirmed aRCC with a clear cell component, including those with sarcomatoid features (sRCC), were randomized 1:1 to receive either nivolumab plus cabozantinib or sunitinib. The primary end point was RECIST v1.1-defined progression-free survival by blinded independent central review (BICR) in all randomized patients. Key secondary end points included overall survival, objective response rate by BICR, and safety.

Overall, 75 patients (11.5%) had sRCC and 557 (85.6%) did not; sRCC status was not reported in 19 patients (2.9%). In total, 34 patients with sRCC received nivolumab and cabozantinib and 41 received sunitinib.

In an interview with CancerNetwork®, Robert J. Motzer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explained the results of the sarcomatoid subgroup analysis with regard to the overall study population.

Transcription:

What we find is that for the most part, the outcomes for the [immuno-oncologic; IO] therapy plus the [a tyrosine kinase inhibitor] are similar [in all treated patients]. It may be a bit inferior with sarcomatoid features compared to [non-sarcomatoid RCC], but it’s really the difference that we see when we compare it with the sunitinib group. Because the sarcomatoid-feature tumors are very resistant to sunitinib, we see that that resistance is released, or it’s overcome, by the IO therapy. So, it’s really more relative to how they did before.

I think it’s very clear that [for] patients who have tumors that contain these sarcomatoid features, a requirement of their therapy is one of these [immuno-oncologic] checkpoint inhibitors in combination [with a VEGF inhibitor].

Reference:

Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin Oncol. 2021;39(suppl 6):308. doi: 10.1200/JCO.2021.39.6_suppl.308

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content